Advanced Search

Show simple item record

dc.contributor.authorÇaycı, F. Şemsa
dc.contributor.authorÇakar, Nilgün
dc.contributor.authorHançer, Veysel Sabri
dc.contributor.authorUncu, Nermin
dc.contributor.authorAcar, Banu
dc.contributor.authorGür, Gökçe
dc.date.accessioned2014-11-27T14:01:29Z
dc.date.available2014-11-27T14:01:29Z
dc.date.issued2012
dc.identifier.citationCayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatric Nephrology. 2012; 27(12):2327-2331. doi: 10.1007/s00467-012-2283-9.en_US
dc.identifier.issn0931-041X
dc.identifier.urihttp://link.springer.com/article/10.1007%2Fs00467-012-2283-9en_US
dc.identifier.urihttps://hdl.handle.net/11446/571en_US
dc.descriptionİstanbul Bilim Üniversitesi, Tıp Fakültesi.en_US
dc.description.abstractBackground Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in childhood. It usually occurs after a prodromal episode of diarrhea and it leads to significant morbidity and mortality during the acute phase. However, cases that start as diarrhea-positive HUS whose renal function fail to recover should be screened for genetic disorders of the complement system, which is called atypical HUS (aHUS). Case-Diagnosis/Treatment We herein report a 10-year-old girl, who initially came with bloody diarrhea and had features of HUS with delayed renal and hematological recovery despite plasma therapy. Eculizumab (600 mg/week) was initiated on day 15 for atypical presentation and later a complement factor I (CFI) mutation was detected. The girl recovered diuresis within 24 h and after the third eculizumab infusion, hemoglobin, platelet, and C3 levels normalized; renal function improved; and proteinuria completely disappeared in 2 weeks. Conclusion It is our belief that eculizumab can be the treatment of choice in children who have plasma exchange-refractory HUS with defective regulation of the alternative complement pathway.en_US
dc.language.isoengen_US
dc.publisherSpringer Verlagen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.titleEculizumab therapy in a child with hemolytic uremic syndrome and CFI mutationen_US
dc.typereporten_US
dc.relation.journalPediatric Nephrologyen_US
dc.contributor.departmentDBÜ, Tıp Fakültesien_US
dc.identifier.issue12
dc.identifier.volume27
dc.identifier.startpage2327
dc.identifier.endpage2331
dc.contributor.authorIDTR132685en_US
dc.contributor.authorIDTR43513en_US
dc.relation.publicationcategoryDiğeren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record